Stock Track | Insilico Medicine Soars 8.98% Intraday on Preclinical Candidate Nomination and Eli Lilly Collaboration

Stock Track04-09

Insilico Medicine's stock soared 8.98% during intraday trading, reflecting strong investor optimism following significant company announcements.

The surge is primarily attributed to the company's nomination of ISM6200 as a preclinical candidate compound (PCC). This potent and selective NR3C1 antagonist, developed using Insilico's Pharma.AI platform, is intended for the treatment of conditions such as ovarian cancer and Cushing's syndrome, and is predicted to have best-in-class potential with a low effective dose in humans.

Further bolstering sentiment is a recent collaboration and license agreement with pharmaceutical giant Eli Lilly. The deal is valued at up to approximately $2.75 billion and includes an upfront payment of $115 million, covering both the licensing of a preclinical pipeline and multiple future drug discovery collaborations supported by Insilico's AI platform.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181951307?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181951307","market":"nz","top_or_hot":-1,"title":"Stock Track | Insilico Medicine Soars 8.98% Intraday on Preclinical Candidate Nomination and Eli Lilly Collaboration","media":"Stock Track","content":"<p>Insilico Medicine's stock soared 8.98% during intraday trading, reflecting strong investor optimism following significant company announcements.</p><p>The surge is primarily attributed to the company's nomination of ISM6200 as a preclinical candidate compound (PCC). This potent and selective NR3C1 antagonist, developed using Insilico's Pharma.AI platform, is intended for the treatment of conditions such as ovarian cancer and Cushing's syndrome, and is predicted to have best-in-class potential with a low effective dose in humans.</p><p>Further bolstering sentiment is a recent collaboration and license agreement with pharmaceutical giant Eli Lilly. The deal is valued at up to approximately $2.75 billion and includes an upfront payment of $115 million, covering both the licensing of a preclinical pipeline and multiple future drug discovery collaborations supported by Insilico's AI platform.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insilico Medicine Soars 8.98% Intraday on Preclinical Candidate Nomination and Eli Lilly Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insilico Medicine Soars 8.98% Intraday on Preclinical Candidate Nomination and Eli Lilly Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-09 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine's stock soared 8.98% during intraday trading, reflecting strong investor optimism following significant company announcements.</p><p>The surge is primarily attributed to the company's nomination of ISM6200 as a preclinical candidate compound (PCC). This potent and selective NR3C1 antagonist, developed using Insilico's Pharma.AI platform, is intended for the treatment of conditions such as ovarian cancer and Cushing's syndrome, and is predicted to have best-in-class potential with a low effective dose in humans.</p><p>Further bolstering sentiment is a recent collaboration and license agreement with pharmaceutical giant Eli Lilly. The deal is valued at up to approximately $2.75 billion and includes an upfront payment of $115 million, covering both the licensing of a preclinical pipeline and multiple future drug discovery collaborations supported by Insilico's AI platform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1181951307","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181951307","pubTimestamp":1775701728,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Insilico Medicine's stock soared 8.98% during intraday trading, reflecting strong investor optimism following significant company announcements.The surge is primarily attributed to the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"个股追踪|Insilico Medicine因临床前候选提名及礼来合作盘中大涨8.98%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine's stock soared 8.98% during intraday trading, reflecting strong investor optimism following significant company announcements.The surge is primarily attributed to the company's nomination of ISM6200 as a preclinical candidate compound (PCC). This potent and selective NR3C1 antagonist, developed using Insilico's Pharma.AI platform, is intended for the treatment of conditions such as ovarian cancer and Cushing's syndrome, and is predicted to have best-in-class potential with a low effective dose in humans.Further bolstering sentiment is a recent collaboration and license agreement with pharmaceutical giant Eli Lilly. The deal is valued at up to approximately $2.75 billion and includes an upfront payment of $115 million, covering both the licensing of a preclinical pipeline and multiple future drug discovery collaborations supported by Insilico's AI platform.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181951307","isCrawlerRequest":true}